Expression and immunogenicity of NY‐ESO‐1 in hepatocellular carcinoma

Background and Aim:  The present study was designed to investigate the expression of and humoral response against NY‐ESO‐1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY‐ESO‐1 mRNA and clinicopathological features.

[1]  M. Ladanyi,et al.  Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 , 2001, International journal of cancer.

[2]  Yao-Tseng Chen,et al.  Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. , 2001, Cancer research.

[3]  N. Altorki,et al.  Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.

[4]  Y. Shiratori,et al.  Des‐γ‐carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma , 2001, Cancer.

[5]  H. El‐Serag,et al.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States , 2001, Hepatology.

[6]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[7]  J. Moringlane,et al.  Expression of cancer testis genes in human brain tumors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  V. Cerundolo,et al.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Masakazu Yamamoto,et al.  Serum levels of des‐γ‐carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma , 2000, Cancer.

[11]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[12]  Lloyd J. Old,et al.  New Paths in Human Cancer Serology , 1998, The Journal of experimental medicine.

[13]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[14]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[15]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Liver Cancer Study Group of Japan.  The general rules for the clinical and pathological study of primary liver cancer , 2006, The Japanese journal of surgery.